Compare Stocks: DMRA, COGT, MIRM, and CGON

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$76.56 +1.9%	$67.12	$23.65 ▼ $77.00	$6.79B	0.23	1.16 million shs	810,778 shs
COGT Cogent Biosciences	$41.53 -2.0%	$37.39	$10.72 ▼ $43.73	$7.10B	0.38	2.24 million shs	1.62 million shs
DMRA Damora Therapeutics, Inc. Common Stock	$29.54 -1.3%	$26.46	$2.45 ▼ $38.33	$1.82B	1.47	388,762 shs	216,195 shs
MIRM Mirum Pharmaceuticals	$98.70 -1.9%	$110.33	$58.48 ▼ $130.00	$6.41B	0.52	899,938 shs	867,966 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	0.00%	+5.49%	-0.19%	+8.34%	+202.21%
COGT Cogent Biosciences	0.00%	+8.89%	+9.06%	+24.31%	+286.77%
DMRA Damora Therapeutics, Inc. Common Stock	0.00%	+3.21%	+4.87%	+22.82%	+785.21%
MIRM Mirum Pharmaceuticals	0.00%	-5.00%	-17.59%	-5.20%	+67.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$76.56 +1.9%	$67.12	$23.65 ▼ $77.00	$6.79B	0.23	1.16 million shs	810,778 shs
COGT Cogent Biosciences	$41.53 -2.0%	$37.39	$10.72 ▼ $43.73	$7.10B	0.38	2.24 million shs	1.62 million shs
DMRA Damora Therapeutics, Inc. Common Stock	$29.54 -1.3%	$26.46	$2.45 ▼ $38.33	$1.82B	1.47	388,762 shs	216,195 shs
MIRM Mirum Pharmaceuticals	$98.70 -1.9%	$110.33	$58.48 ▼ $130.00	$6.41B	0.52	899,938 shs	867,966 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	0.00%	+5.49%	-0.19%	+8.34%	+202.21%
COGT Cogent Biosciences	0.00%	+8.89%	+9.06%	+24.31%	+286.77%
DMRA Damora Therapeutics, Inc. Common Stock	0.00%	+3.21%	+4.87%	+22.82%	+785.21%
MIRM Mirum Pharmaceuticals	0.00%	-5.00%	-17.59%	-5.20%	+67.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.71	Moderate Buy	$83.18	8.65% Upside
COGT Cogent Biosciences	2.85	Moderate Buy	$45.90	10.52% Upside
DMRA Damora Therapeutics, Inc. Common Stock	2.92	Moderate Buy	$44.00	48.95% Upside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$137.33	39.14% Upside

Current Analyst Ratings Breakdown

Latest DMRA, COGT, MIRM, and CGON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$81.00 ➝ $79.00
8/7/2026	CGON CG Oncology	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$82.00 ➝ $85.00
8/7/2026	CGON CG Oncology	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$82.00 ➝ $85.00
8/6/2026	MIRM Mirum Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
8/6/2026	MIRM Mirum Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$123.00
8/6/2026	MIRM Mirum Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$137.00
8/6/2026	MIRM Mirum Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$148.00 ➝ $135.00
8/6/2026	MIRM Mirum Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/6/2026	MIRM Mirum Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$145.00 ➝ $140.00
8/6/2026	MIRM Mirum Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$146.00 ➝ $137.00
8/6/2026	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$185.00 ➝ $140.00

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$4.04M	1,679.77	N/A	N/A	$9.33 per share	8.21
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$3.84 per share	N/A
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	($110.11) per share	N/A
MIRM Mirum Pharmaceuticals	$521.31M	12.29	$0.05 per share	1,974.34	$6.12 per share	16.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-26.58%	-25.34%	N/A
COGT Cogent Biosciences	-$328.94M	-$2.17	N/A	N/A	N/A	N/A	-104.27%	-54.64%	8/10/2026 (Estimated)
DMRA Damora Therapeutics, Inc. Common Stock	-$209.84M	-$5.58	N/A	N/A	N/A	N/A	-428.30%	-114.62%	N/A
MIRM Mirum Pharmaceuticals	-$23.36M	-$14.55	N/A	N/A	N/A	-139.18%	-36.28%	-8.54%	N/A

Latest DMRA, COGT, MIRM, and CGON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	COGT Cogent Biosciences	-$0.5550	-$0.52	+$0.0350	-$0.52	$0.00 million	N/A
8/10/2026	Q2 2026	DMRA Damora Therapeutics, Inc. Common Stock	-$0.4470	-$0.39	+$0.0570	-$0.39	N/A	N/A
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million
5/13/2026	Q1 2026	DMRA Damora Therapeutics, Inc. Common Stock	-$0.3878	-$0.62	-$0.2322	-$0.62	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	31.30	31.25
COGT Cogent Biosciences	0.41	15.14	15.14
DMRA Damora Therapeutics, Inc. Common Stock	N/A	22.49	22.48
MIRM Mirum Pharmaceuticals	1.28	2.86	2.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
COGT Cogent Biosciences	N/A
DMRA Damora Therapeutics, Inc. Common Stock	14.20%
MIRM Mirum Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
COGT Cogent Biosciences	6.59%
DMRA Damora Therapeutics, Inc. Common Stock	0.40%
MIRM Mirum Pharmaceuticals	8.32%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	61	88.64 million	84.39 million	Optionable
COGT Cogent Biosciences	80	170.87 million	159.61 million	Optionable
DMRA Damora Therapeutics, Inc. Common Stock	40	61.55 million	61.31 million	No Data
MIRM Mirum Pharmaceuticals	140	64.93 million	59.53 million	Optionable

DMRA, COGT, MIRM, and CGON Headlines

Recent News About These Companies

Hennion & Walsh Asset Management Inc. Sells 56,100 Shares of Mirum Pharmaceuticals, Inc. $MIRM

August 10 at 5:35 AM | marketbeat.com

Q3 EPS Forecast for Mirum Pharmaceuticals Boosted by Analyst

August 10 at 1:13 AM | americanbankingnews.com

Q3 EPS Estimate for Mirum Pharmaceuticals Raised by Analyst

August 10 at 1:11 AM | marketbeat.com

Mirum Pharmaceuticals (NASDAQ:MIRM) Upgraded to Hold at Wall Street Zen

August 8 at 2:24 AM | americanbankingnews.com

Wall Street Zen Upgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to "Hold"

August 8 at 2:23 AM | marketbeat.com

Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down After Earnings Miss

August 8 at 1:40 AM | americanbankingnews.com

The Manufacturers Life Insurance Company Grows Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM

August 7 at 4:40 AM | marketbeat.com

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 7 at 4:13 AM | marketbeat.com

Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026 | finance.yahoo.com

TD Cowen Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $140.00

August 6, 2026 | marketbeat.com

Citizens Says FDA’s 'Unexpected' Phase 3 Request Clouds Mirum’s Near-Term Outlook – MIRM Stock Crashes 15%

August 6, 2026 | msn.com

Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised

August 6, 2026 | zacks.com

Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down Following Weak Earnings

August 6, 2026 | marketbeat.com

Citizens Jmp Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $137.00

August 6, 2026 | marketbeat.com

HC Wainwright Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $140.00

August 6, 2026 | marketbeat.com

Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells $193,733.60 in Stock

August 6, 2026 | insidertrades.com

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript

August 5, 2026 | seekingalpha.com

Mirum Pharmaceuticals Q2 Earnings Call Highlights

August 5, 2026 | marketbeat.com

Mirum Pharmaceuticals (NASDAQ:MIRM) Announces Earnings Results, Misses Estimates By $0.32 EPS

August 5, 2026 | marketbeat.com

Compared to Estimates, Mirum Pharmaceuticals (MIRM) Q2 Earnings: A Look at Key Metrics

August 5, 2026 | zacks.com

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimates

August 5, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA, COGT, MIRM, and CGON Company Descriptions

CG Oncology NASDAQ:CGON

$76.56 +1.46 (+1.94%)

As of 04:00 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Cogent Biosciences NASDAQ:COGT

$41.53 -0.86 (-2.03%)

As of 04:00 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

$29.54 -0.38 (-1.27%)

As of 04:00 PM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Mirum Pharmaceuticals NASDAQ:MIRM

$98.70 -1.95 (-1.94%)

As of 04:00 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DMRA, COGT, MIRM, and CGON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DMRA, COGT, MIRM, and CGON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DMRA, COGT, MIRM, and CGON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA, COGT, MIRM, and CGON Company Descriptions

CG Oncology NASDAQ:CGON

Cogent Biosciences NASDAQ:COGT

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

Mirum Pharmaceuticals NASDAQ:MIRM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DMRA, COGT, MIRM, and CGON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DMRA, COGT, MIRM, and CGON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DMRA, COGT, MIRM, and CGON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA, COGT, MIRM, and CGON Company Descriptions

CG Oncology NASDAQ:CGON

Cogent Biosciences NASDAQ:COGT

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

Mirum Pharmaceuticals NASDAQ:MIRM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools